Pharmaceuticals, Biotechnology and Life Sciences
Don't spend too much on your repeated translations.
Cut costs with Vikler Media. Visit: media.vikler.net
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will be focused on developing new therapies for autoimmune diseases that...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast density this Christmas. Dense breast tissue is a relatively unknown but common breast cancer risk factor, which additionally makes it...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
Over-65s across the UK are set to benefit from potentially life-changing new treatment options for conditions like cancer and cardiovascular...
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage…
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world’s most advanced…
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented…
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron Mr. Willard has a 30+…
WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract…
CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount…
Submission marks key step in study of mesenchymal stem cell therapy to treat symptomatic cartilage defects in patients with knee…
MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel…
